CurrentOscar HealthPolicy N/A

Prostate Specific Antigen (PSA) Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines clinical coverage criteria, indications, limitations, and guideline context for total PSA and related PSA-based tests for prostate cancer screening, diagnosis, monitoring, and follow-up for Oscar Health members.

Policy Summary

PayerOscar Health

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionDocument shared decision-making and repeat PSA values; repeat PSA is recommended to confirm a newly elevated result before secondary testing or biopsy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

45age to begin avg-risk screening

40age to begin higher-risk screening

>3elevated PSA (<76 yrs)

≥4elevated PSA (≥76 yrs)

2-4 yrs

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentOscar HealthPolicy N/A

Prostate Specific Antigen (PSA) Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerOscar Health

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionDocument shared decision-making and repeat PSA values; repeat PSA is recommended to confirm a newly elevated result before secondary testing or biopsy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

45age to begin avg-risk screening

40age to begin higher-risk screening

>3elevated PSA (<76 yrs)

≥4elevated PSA (≥76 yrs)

2-4 yrs

repeat intervals (low PSA)

4PSA procedure codes listed

Coverage, Indications, and Limitations

Screening and follow-up coverage criteria

Covered when criteria below are met:

Initial average-risk screening: Initial screening with total PSA MEETS CRITERIA for average-risk individuals 45 years of age and olderage >=45

See Note 1 regarding testing after 75 years

Annual screening for higher-risk individuals: Annual screening with total PSA MEETS CRITERIA for individuals 40 years and older when any of: (a) African ancestry, (b) germline mutations that increase prostate cancer risk, (c) suspicious family historyage >=40 and at least one risk factor

See Note 1

Repeat screening intervals based on prior PSA: For individuals with prior total PSA results, repeat screening MEETS CRITERIA with frequency: (a) if age <76 and total PSA <1 ng/mL: repeat every 2-4 years; (b) if age <76 and total PSA 1-3 ng/mL: repeat every 1-2 years; (c) if age >75 and total PSA <4 ng/mL with normal DRE and no biopsy indication: repeat in select patients at 1-3 year intervalsprior PSA ranges and age

DRE if done noted in criteria

Follow-up for elevated PSA or suspicious DRE: For individuals with elevated PSA (see Note 2 thresholds) or suspicious DRE, follow-up total PSA in 6-12 months MEETS CRITERIAelevated PSA >3 ng/mL (<76) or >=4 ng/mL (>=76)

See Note 2

Percent free PSA after negative biopsy: For individuals with elevated total PSA and an initial negative biopsy, follow-up testing with percent free PSA MEETS CRITERIA (no more often than follow-up total PSA)post-negative biopsy

Total PSA other covered indications: Total PSA testing MEETS CRITERIA for any of: (a) initial diagnosis in individuals with signs or symptoms of prostate cancer, (b) follow-up of individuals with current or prior prostate cancer diagnosis, (c) ongoing monitoring after tumor resection or prostatectomy, (d) monitoring response to prostate cancer therapy, (e) detecting disease recurrenceclinical indication

See Note 3 for common symptoms

Not recommended / Not covered testing

The following testing does NOT meet criteria:

Excluded PSA-based tests: (a) Percent free PSA as a first-line screening test for prostate cancer; (b) Percent free PSA or free-to-total PSA ratio for routine screening; (c) Complexed PSA testing

Lack of sufficient published evidence

Screening, follow-up, and monitoring criteria from cited guidelines

Covered or recommended actions per cited guidelines when shared decision-making and appropriate clinical context apply

Shared decision-making before screening: Clinicians should engage in shared/informed decision-making with patients (particularly ages ~45–75 depending on guideline) and proceed based on patient values and preferences.

Supported by USPSTF, ACP, AUA/SUO, NCCN, ACS

Age-based initiation and risk-stratified start: Offer/consider baseline PSA: ACS/NCCN/AUA suggest starting at 50 for average risk, 45 for increased risk, and 40 for highest risk or specific high-risk groups (African ancestry, strong family history, germline mutations).ages 40–50 depending on risk

See guideline-specific age windows

Repeat and monitoring intervals based on PSA: If PSA <1 ng/mL, re-screen every 2–4 years (or per guideline); if PSA 1–3 ng/mL, re-screen every 1–2 years; if PSA ≥3 ng/mL (or DRE very suspicious) repeat PSA and consider secondary testing/biomarker/imaging and potential biopsy.

ESMO: Targeted screening and exclusions

ESMO position (summary):

ESMO targeted screening recommendations: Offer early PSA testing only for men >50 years OR men >45 years with a family history of prostate cancer OR African American men >45 years OR BRCA1/2 carriers >40 years; do not screen asymptomatic men with life expectancy <10 years; recommend against screening asymptomatic men over 70.

Derived from ESMO statements in chunk 36

EAU: Counselling before PSA testing

EAU position (summary):

EAU counselling requirement: Do not subject men to PSA testing without counselling them on the potential risks and benefits (strong recommendation).

Repeated strongly in chunks 43 and 49

AACU: Molecular testing recommendation

AACU advisory note:

AACU molecular/germline testing: Encourages use of tissue-based molecular testing for risk stratification and pursuing germline testing when appropriate; supports further research.

Advisory rather than coverage criteria

Risk-adapted early detection

Covered when following risk-adapted early detection criteria are met

Elevated-risk groups: Men >50 years; men >45 years with family history of prostate cancer; men of African descent >45 years; men with BRCA2 mutations >40 years.age/family/race/genetic criteria
Recommendation strength varies by subgroup.
PSA-based follow-up: Follow-up intervals of two years for those initially at risk based on initial PSA level (examples: <1 ng/mL at 40 years; <2 ng/mL at 60 years).PSA thresholds as noted
Risk-adapted strategy based on initial PSA.

The policy specifies that percent free PSA (%fPSA) as a first-line screening test, percent free-to-total PSA ratio for routine screening, and complexed PSA testing do not meet criteria. These tests are listed as excluded because there is insufficient published scientific evidence demonstrating that they are required and beneficial as routine first-line screening tools for prostate cancer.

Multiple guideline bodies discourage population-based PSA screening and emphasize informed decision-making. The USPSTF advises clinician–patient discussion about benefits and harms and recommends against PSA-based screening in men over 70 years. The ACP similarly requires informed discussion and recommends against screening in individuals under 50 or over 70 years, and advises that asymptomatic men over 75 or those with life expectancy <10 years should not be offered screening.

ESMO advises against population-based screening because harms outweigh mortality benefit. It recommends offering early PSA testing only to selected higher-risk groups (men >50 years; men >45 years with family history; African American men >45 years; BRCA1/2 carriers >40 years) and states that screening should not be performed in asymptomatic men with life expectancy <10 years or in asymptomatic men over 70 years.

The EAU endorses a risk-adapted approach and explicitly notes stopping early detection efforts in men with limited expected benefit: clinicians should stop early diagnosis of prostate cancer in men with life-expectancy of <15 years, stating these men are unlikely to benefit from screening or early detection strategies.

The reference and publication-history sections of the policy list supporting literature and evidence sources but do not contain any explicit additional exclusions beyond those stated in the coverage criteria and guideline summaries.

Tests enumerated in the exclusions (for example, %fPSA as a first-line screen, routine free-to-total PSA ratio testing, and complexed PSA) are designated as not meeting criteria because the policy identifies a lack of available published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment in routine screening contexts.

Guideline bodies commonly advise against routine PSA-based screening in older men and in those with limited life expectancy. The USPSTF and ACP recommend against routine screening in men over about 70 years (and some guidance extends to >75 years), and many organizations state screening should not be offered to men with life expectancy <10 years because potential harms outweigh benefits.

ESMO explicitly states that population-based PSA screening is not recommended because the reduction in mortality does not offset harms such as overdiagnosis and overtreatment; therefore routine widespread screening is discouraged.

Within the sections listing evidence and publication history there are no standalone 'not medically necessary' declarations beyond the exclusions and guideline-derived recommendations summarized elsewhere in the policy.

Procedure Codes and Thresholds

Applicable CPT/HCPCS Procedure CodesCPT | HCPCS

84152	Prostate specific antigen (PSA); complexed (direct measurement)
84153	Prostate specific antigen (PSA); total
84154	Prostate specific antigen (PSA); free
G0103	Prostate cancer screening; prostate specific antigen test (PSA)

Elevated PSA thresholds

Threshold for individuals <76 yearsElevated PSA requiring further evaluation: total PSA > 3 ng/mL

Threshold for individuals ≥76 yearsElevated PSA requiring further evaluation: total PSA ≥ 4 ng/mL

Source noteDefined in policy Notes (Note 2) as age-specific elevated PSA thresholds

PSA level thresholds

Less than 1 ng/mLRecommendation: re-screen infrequently (examples: repeat at ages noted or every 2–4 years depending on age)

1–3 ng/mLRecommendation: repeat PSA testing every 1–2 years (or 2–4 years depending on proximity to 1 vs 3 ng/mL)

Authorization, Documentation, and Billing Guidance

Prior Authorization

Authorization and medical necessity — ensure services meet policy

Policy notes that services must meet authorization and medical necessity guidelines; providers should ensure submitted services meet those requirements and follow applicable reimbursement rules.

Prior Authorization

Document prior and confirmatory PSA before secondary testing

If PSA is elevated and the provider pursues secondary biomarker testing or imaging, documentation of prior PSA results and any confirmatory repeat PSA should accompany requests for further testing.

Include prior PSA values and evidence of a repeat/confirmatory PSA before ordering secondary biomarkers or imaging.
Support requests with clinical notes documenting DRE findings and reason for secondary testing.

Clinical Background and Rationale

Background: Prostate-specific antigen (PSA) is a glycoprotein produced by normal and neoplastic prostate tissue that circulates in both free and bound forms. PSA testing is used across screening, diagnostic, monitoring, and treatment contexts, but routine use is guided by risk stratification and shared decision-making because of risks of false positives, overdiagnosis, and potential harms from downstream interventions.

Key Terms and Biomarkers

Total PSA

DefinitionTotal PSA measures the amount of all PSA identified in a serum sample, including bound and unbound forms.

Components detectedIncludes PSA bound to alpha-1 antichymotrypsin (majority) and unbound (free) PSA; PSA–alpha-2 macroglobulin is present but not detected by standard assays.

Clinical roleTotal PSA is used for screening, diagnosis, monitoring, and treatment management of prostate cancer.

Free PSA

DefinitionFree PSA is the unbound (enzymatically inactive) form of PSA present in serum; expressed as percent of total PSA.

Proportion in serumFree PSA constitutes approximately 5–50% of serum PSA samples depending on individual factors.

Publication and Review History

2026-10-01effective_dateLatest

Policy became effective on 2026-10-01.

2026-06-16governance_approval

Policy governance review and approval recorded on 06/16/2026 (last review date).

Policy Summary

PayerOscar Health

PolicyProstate Specific Antigen (PSA) Testing

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionDocument shared decision-making and repeat PSA values; repeat PSA is recommended to confirm a newly elevated result before secondary testing or biopsy.

SourceLink

On This Page

PSA breakpoints <1, 1–3, ≥3 ng/mL

NCCN, MSK, AUA/SUO, ACS guidance

Confirmatory testing before invasive steps: For a newly elevated PSA, clinicians should repeat the PSA prior to ordering secondary biomarker testing, imaging, or proceeding to biopsy.

AUA/SUO and NCCN recommend confirmation

Use of secondary biomarkers and imaging: Consider %fPSA, other biomarkers, and mpMRI to inform biopsy decisions; %fPSA has FDA-labeled utility in certain PSA ranges (e.g., 4–10 ng/mL) to reduce unnecessary biopsies.PSA 4–10 ng/mL for %fPSA consideration

NCCN discussion of biomarkers and mpMRI

Age and life-expectancy-based discontinuation: Do not routinely screen men over ~70 (USPSTF recommends against over 70; others advise individualized decisions over 75); discontinue screening in those with life expectancy <10 years unless specific circumstances justify testing.age >70–75 or life expectancy <10 years

USPSTF, ACP, ESMO, ACS

Monitoring after treatment or in advanced disease: For patients treated with curative intent: PSA every 6–12 months for first 5 years then annually; in high-risk recurrence or on ADT/mHSPC/nmCRPC, obtain serial PSA every 3–6 months and calculate kinetics when indicated.3–6 months or 6–12 months depending on context

NCCN and AUA/SUO clinical principles

≥3 ng/mLAction: repeat PSA and consider secondary testing, imaging, biomarker evaluation, or biopsy if persistently elevated

4–10 ng/mLContext: PSA window where %fPSA (percent free PSA) has FDA-labeled utility to reduce unnecessary biopsies

PSA reference-based age thresholds

Example: PSA at 40 yearsA PSA level < 1 ng/mL at 40 years is cited as an example threshold in a risk-adapted follow-up strategy

Example: PSA at 60 yearsA PSA level < 2 ng/mL at 60 years is cited as an example threshold in a risk-adapted follow-up strategy

Use in strategyEAU recommends risk-adapted early detection with follow-up intervals based on these reference PSA values

Documentation Required

No explicit prior‑authorization rules — document clinical rationale

The policy does not list explicit universal prior‑authorization rules for PSA or secondary tests in these sections; providers should nevertheless document counselling and clinical rationale when ordering screening or secondary tests.

No specific PA rules stated in the cited guideline summaries.
Document SDM/counselling per EAU guidance when ordering PSA screening.

Billing Rule

Use listed PSA procedure codes and follow coding guidelines

Procedure codes for PSA testing are listed (84152, 84153, 84154, G0103); the policy does not state a universal prior‑authorization requirement for these codes in this excerpt — code and bill per industry standards.

Use CPT/HCPCS codes 84152, 84153, 84154, and G0103 as applicable.
Follow standard coding guidelines when submitting claims.

Prior Authorization

No PA specified here; follow applicable government policies

No prior‑authorization requirements are specified in the reference and publication‑history sections; when applicable federal or state government policy conflicts with this policy, the government policy governs determinations.

If a government (LCD/NCD/state Medicaid) policy applies, follow that policy for coverage determinations.
Absence of PA language here does not preclude PA requirements elsewhere in payer systems.

Step Therapy

Repeat PSA to confirm elevation before secondary testing

Repeat PSA is recommended to confirm a newly elevated result before ordering secondary biomarkers, imaging, or proceeding to biopsy; consideration of %fPSA and other biomarkers is suggested in appropriate PSA ranges.

Repeat the PSA prior to secondary biomarker testing, imaging, or biopsy for newly elevated values.
Consider %fPSA for PSA levels in ranges where it is validated (e.g., 4–10 ng/mL) per NCCN guidance.

Note

Consider molecular and germline testing per AACU guidance

AACU advises using tissue‑based molecular testing for risk stratification and encourages germline testing when appropriate; this is advisory and not imposed as step‑therapy.

Consider tissue‑based molecular testing for treatment risk stratification.
Pursue germline testing when clinically appropriate and documented.

Note

Biomarker options are investigational — document rationale

Newer biomarkers and panels may aid risk prediction but require further validation; no step‑therapy sequencing or mandatory biomarker testing is specified.

Use biomarker tests cautiously and document rationale; recognize need for further validation per EAU guidance.
No mandatory step‑therapy ordering of biomarkers is specified in these excerpts.

Documentation Required

Submit accurate documentation and coding to avoid denials

Providers must submit accurate documentation of services performed and code claims according to industry standards; failure to follow coding/billing guidelines may lead to claim denial or recoupment.

Ensure accurate coding (CPT/HCPCS/ICD‑10) and supporting clinical documentation.
Retain documentation of counselling, PSA values, repeat testing, and justification for secondary tests.

Documentation Required

Document SDM, prior PSA values, and confirmatory testing

Document shared/informed decision‑making discussions, record prior PSA values and health status, and use these to guide screening frequency and continuation; repeat PSA is recommended prior to secondary testing.

Record SDM discussion content, patient preferences, and estimated life expectancy.
Include prior PSA results and any confirmatory repeated PSA in the record before ordering biomarkers or imaging.

Documentation Required

Counsel and document risks/benefits before PSA testing

Document that the patient received counselling on potential risks and benefits prior to PSA testing in accordance with EAU guidance: 'Do not subject men to PSA testing without counselling them on the potential risks and benefits.'

Include counselling notes that describe risks, benefits, and alternatives to PSA screening.
Obtain and document patient preference after counselling before proceeding with screening.

Documentation Required

Document risk factors and life‑expectancy before risk‑adapted detection

Before offering a risk‑adapted early detection strategy, document risk factors (age, family history, race, BRCA2 status) and estimate life expectancy; offer individualized strategy only for men with life expectancy of at least 15 years.

Record age, family history, race, and genetic risk factors in the chart.
Document life‑expectancy estimation and counselling that supports a risk‑adapted plan.

Prior Authorization

Require repeat PSA in the record before secondary testing or biopsy

Repeat PSA prior to secondary biomarker testing, imaging, or biopsy is explicitly recommended by guideline panels; ensure a repeat/confirmatory PSA is in the record before proceeding.

Perform and document a repeat PSA for newly elevated results before ordering %fPSA, mpMRI, or biopsy.
Note DRE findings and workup for benign causes when documenting the decision.

Documentation Required

Document indication and intent for molecular/germline testing

When considering molecular or germline testing, document the clinical indication and that testing is being used for risk stratification or treatment decision‑making; AACU encourages these tests but does not mandate them as prior steps.

Document indication for tissue‑based molecular testing and how results will affect management.
Document rationale for germline testing and patient counselling/consent.

Documentation Required

Document biomarker rationale and applicable PSA range

When ordering biomarkers, note that newer assays may help predict indolent disease but require further validation; document why a given biomarker was chosen and applicable PSA range (e.g., %fPSA utility cited for PSA 4–10 ng/mL).

If ordering %fPSA, document that PSA falls within the clinically supported range (e.g., 4–10 ng/mL) and the purpose (reduce unnecessary biopsy).
Record that biomarker selection considered guideline limitations and validation status.

Denial Risk

Denial risk for incorrect coding or insufficient documentation

Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed or if documentation is inaccurate; follow industry coding standards and retain supporting records.

Adhere to AMA CPT, HCPCS, ICD‑10, and payer coding guidance when submitting claims.
Maintain documentation of counselling, PSA values, repeat testing, and ordering rationale to support medical necessity.

Denial Risk

Avoid screening men with limited life‑expectancy (<10 years)

Do not routinely screen asymptomatic men with limited life expectancy (life‑expectancy <10 years per ESMO); screening in this population may be considered inappropriate and could be denied.

Assess and document estimated life expectancy before screening.
Avoid routine PSA screening in men with life expectancy <10 years; for risk‑adapted strategies prefer life‑expectancy ≥15 years as documented.

Interpretive valueThe ratio of free to total PSA may help distinguish benign from malignant prostate conditions when used as an adjunctive measure.

percent free PSA (%fPSA)

DefinitionPercent free PSA (%fPSA) is the ratio of unbound (free) PSA to total PSA used as a secondary biomarker to improve detection and reduce unnecessary biopsies.

FDA-labeled utilityThe FDA approved %fPSA for early detection in individuals aged ≥50 years with non-suspicious DRE and PSA 4–10 ng/mL; a 25% fPSA cutoff detected 95% of cancers while avoiding 20% of unnecessary biopsies in the referenced study.

Clinical useIncluded in NCCN guidance as an option for individuals with prior negative biopsy or within recommended PSA windows (commonly 4–10 ng/mL).

PSA kinetics (PSADT)

DefinitionPSA kinetics (PSA doubling time, PSADT) refers to calculation of PSA change over time using serial measurements to assess disease trajectory.

Use in advanced diseaseIn nmCRPC and mHSPC, serial PSA measurements every 3–6 months are recommended and PSADT is calculated to inform prognosis and management.

Monitoring intervalsSerial PSAs at defined intervals (e.g., 3–6 months) are standard to calculate kinetics in castration-resistant and metastatic settings.

High-risk groups (per ESMO)

Age >50 yearsOffer early PSA testing for men >50 years (ESMO; EAU supports offering early testing in elevated-risk contexts).

Men >45 years with family historyOffer early PSA testing for men >45 years with a family history of prostate cancer.

African American men >45 yearsOffer early PSA testing for African American men >45 years due to higher risk.

BRCA1/2 carriers >40 yearsOffer early PSA testing for BRCA1/2 carriers older than 40 years.

Screening exclusion (per ESMO)

Life-expectancy <10 yearsDo not screen asymptomatic men with life expectancy <10 years (ESMO recommendation).

Asymptomatic men >70 yearsESMO recommends against screening asymptomatic men over 70 years; NCCN/other guidelines also discourage routine screening in older age groups without individualized consideration.

Testing after 75 yearsNCCN: testing after 75 years should be limited to very healthy men with little or no comorbidity and only in select circumstances (Note 1).

Prostate Health Index (phi)

DefinitionProstate Health Index (phi) is an In Vitro Diagnostic Multivariate Index Assay calculated from total PSA, free PSA, and [-2] proPSA (Access Hybritech p2PSA).

FDA contextAccess Hybritech p2PSA assay (Beckman Coulter) was FDA approved to be used with total and free PSA to calculate phi (FDA approval cited 2012).

Clinical rolePhi is used as a multivariate index assay to improve detection and risk stratification in appropriate PSA windows.

PSA influences

Medication effectsStudies describe that medications such as finasteride, statins, NSAIDs, and acetaminophen can alter total and free PSA levels, affecting interpretation.

Inflammation effectsHistologic inflammation can affect total and free PSA values and should be considered when interpreting results.

Reference examplesReferenced literature includes analyses of medication impact and inflammation on PSA (see listed evidence references).

Guideline sources

Major guideline sources citedPolicy cites AUA/SUO, NCCN, EAU, USPSTF, ACS, CDC, NCI, and other specialty society guidance to inform screening recommendations.

NCCN and EAU specificsNCCN guidance used for repeat intervals and biomarker discussion; EAU provides recommendations for risk-adapted early detection and counselling.

ESMO positionESMO recommendations inform exclusions (e.g., life expectancy thresholds) and targeted screening groups.